JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Tumour vascularisation: a druggable target.

Tumour growth, spreading and metastasis require the development of a local vasculature. There have been great advances in the understanding of how this new vasculature arises, particularly in our increased knowledge of the process of angiogenesis, Although, a vast number of pro-angiogenic and anti-angiogenic mediators have been identified, one of the key signalling processes in the development of the tumour vasculature is the hypoxia-induced stimulation of vascular endothelial cell growth factors (VEGFs) production. Anti-VEGF therapy therefore not only provides a new paradigm for limiting tumour growth via targeting angiogenesis, but also provides prototypic agents to test the hypothesis that by controlling the development of the tumour vasculature we are able to limit, and potentially stop, tumour growth and spreading.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app